Renata Ferrari1, Laura M O Caram2, Suzana E Tanni3, Irma Godoy4, Sergio Alberto Rupp de Paiva5. 1. Botucatu Medical School, UNESP - Univ Estadual Paulista, Botucatu Campus, Department of Internal Medicine, Pneumology Area, São Paulo, Brazil. Electronic address: renataferrarifisio@gmail.com. 2. Botucatu Medical School, UNESP - Univ Estadual Paulista, Botucatu Campus, Department of Internal Medicine, Pneumology Area, São Paulo, Brazil. Electronic address: laucaram@gmail.com. 3. Botucatu Medical School, UNESP - Univ Estadual Paulista, Botucatu, Brazil. Electronic address: suzanapneumo@gmail.com. 4. Botucatu Medical School, UNESP - Univ Estadual Paulista, Botucatu Campus, Department of Internal Medicine, Pneumology Area, São Paulo, Brazil. Electronic address: irma@fmb.unesp.br. 5. Botucatu Medical School, UNESP - Univ Estadual Paulista, Botucatu Campus, Department of Internal Medicine, Internal Medicine Area, São Paulo, Brazil. Electronic address: paiva@fmb.unesp.br.
Abstract
OBJECTIVE: To investigate the relationship between Vitamin D and exacerbation in COPD patients. METHODS: The PubMed database was searched for articles published from 2012 onwards using search terms related to Vitamin D and exacerbation in COPD patients. Meta-analysis, clinical trials, observational studies, and human studies were included. Non-English articles or articles with full text unavailable were excluded; a total of 15 articles were selected. RESULTS: The association between exacerbation frequency and Vitamin D levels in observational studies remains controversial, however, meta-analysis revealed a negative association between serum Vitamin D and exacerbation. Also, two clinical trials showed that Vitamin D3 supplementation in COPD patients reduced the risk of moderate and severe exacerbation. Vitamin D binding protein (VDBP) polymorphisms seem to affect patient exacerbation susceptibility. CONCLUSIONS: Few studies in literature have data related to diet, 25-hydroxyVitamin D [25(OH)D] and polymorphism in COPD exacerbation. One clinical trial indicates Vitamin D supplementation plays a role in COPD patients with hypovitaminosis D in preventing exacerbations. Further studies are needed to elucidate the role of Vitamin D in this population and to establish the best marker for Vitamin D, which patient subgroups will benefit, and the best supplement dosage without leading to toxicity.
OBJECTIVE: To investigate the relationship between Vitamin D and exacerbation in COPDpatients. METHODS: The PubMed database was searched for articles published from 2012 onwards using search terms related to Vitamin D and exacerbation in COPDpatients. Meta-analysis, clinical trials, observational studies, and human studies were included. Non-English articles or articles with full text unavailable were excluded; a total of 15 articles were selected. RESULTS: The association between exacerbation frequency and Vitamin D levels in observational studies remains controversial, however, meta-analysis revealed a negative association between serum Vitamin D and exacerbation. Also, two clinical trials showed that Vitamin D3 supplementation in COPDpatients reduced the risk of moderate and severe exacerbation. Vitamin D binding protein (VDBP) polymorphisms seem to affect patient exacerbation susceptibility. CONCLUSIONS: Few studies in literature have data related to diet, 25-hydroxyVitamin D [25(OH)D] and polymorphism in COPD exacerbation. One clinical trial indicates Vitamin D supplementation plays a role in COPDpatients with hypovitaminosis D in preventing exacerbations. Further studies are needed to elucidate the role of Vitamin D in this population and to establish the best marker for Vitamin D, which patient subgroups will benefit, and the best supplement dosage without leading to toxicity.
Authors: Auyon J Ghosh; Matthew Moll; Lystra P Hayden; Jessica Bon; Elizabeth Regan; Craig P Hersh Journal: BMC Pulm Med Date: 2020-05-04 Impact factor: 3.317
Authors: Friederike Maretzke; Angela Bechthold; Sarah Egert; Jana B Ernst; Debora Melo van Lent; Stefan Pilz; Jörg Reichrath; Gabriele I Stangl; Peter Stehle; Dorothee Volkert; Michael Wagner; Julia Waizenegger; Armin Zittermann; Jakob Linseisen Journal: Nutrients Date: 2020-03-31 Impact factor: 5.717